ERBB2 and neoplasm: The risk of recurrence and indication to administer chemotherapy is largely dependent on the classical clinic-pathological prognostic factors of tumour size, involvement of lymph nodes, histologic grade, expression of hormone receptors, and human epidermal growth factor receptor 2 (HER2) amplification [2,3,4,5].